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Abstract
The aim of this study was to describe the immediate and long-term prognosis of a contemporary cohort of patients with left-sided
infective endocarditis (LSIE). A prospective observational cohort study was conducted in a referral centre. Between January 2000 and
December 2011, all consecutive adult patients with LSIE were followed-up until death, relapse, recurrence, need for late surgery, or last
control. During the active phase of IE, 174 of 438 patients underwent surgery (40% overall; 43% native valve (NVIE), 30% prosthetic
valve (PVIE)) and 125 died (29% overall; 26% NVIE, 39% PVIE). The median follow-up in survivors was 3.2 years (interquartile range
(IQR) 1.0–6.0 years). Relapses occurred in seven patients (2.2%; 95% CI, 1.1–4.5) and recurrences in eight (2.6%; 95% CI, 1.3–5.0), with
an incidence density of 0.0067 per patient-year (95% CI, 0.0029–0.0133) and high mortality (75% of recurrences). Only four of 130 sur-
vivors (3.1%; 95% CI, 1.2–7.6) who were treated surgically during the active phase of the disease, and 14/183 (7.7%; 95% CI, 4.6–12.4)
of those not undergoing surgery needed operation during follow-up (p 0.09). In the 313 survivors, actuarial survival was 86% at 1 year
(87% NVIE, 83% PVIE), 79% at 2 years (81% NVIE, 72% PVIE) and 68% at 5 years (71% NVIE, 57% PVIE). At 1 year, 115 of 397 patients
(29.0%; 95% CI, 24.7–33.6) remained alive, with no surgery requirement, relapse or recurrence. LSIE is associated with considerable in-
hospital and long-term mortality, especially PVIE. However, relapses, recurrences and the need for late surgery are uncommon.
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Introduction
Infective endocarditis (IE) is a severe devastating disease,
with an in-hospital mortality ranging from 17 to 30% [1–3].
Numerous contemporary studies have explored the risk fac-
tors for death in IE [1,4–6]. However, there is little informa-
tion about the actual causes of in-hospital mortality in this
condition [7–9] and much less effort has been dedicated to
the current long-term outcome of patients surviving IE.
In 1992, our group published a 15-year cohort study
describing the incidence of long-term complications of native
valve IE (NVIE) in non-addicts [10], and of late prosthetic
valve IE (PVIE) [11]. Since then, the epidemiology of IE has
changed dramatically [12]. However, several of the related
studies are not contemporary, do not differentiate between
PVIE and NVIE [13,14] or between left- and right-sided IE
episodes, do not distinguish between relapse and recurrence,
or have several types of selection bias [13,15].
Thus, the aims of this study were to describe the causes
and risk factors related to in-hospital mortality, the risk of
in-hospital and 1-year mortality according to surgical indica-
tion and the long-term outcome (relapse, recurrence, need
for heart surgery, and mortality) of a contemporary cohort
of patients with left-sided IE.
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Patients and Methods
Design, patients and settings
This prospective, observational cohort study was performed
at Hospital Universitari Vall d’Hebron, a 1000-bed teaching
hospital in Barcelona (Spain) with all major medical and surgi-
cal departments, and a referral centre for cardiac surgery.
All consecutive adult patients (‡18 years of age) with a diag-
nosis of left-sided IE (LSIE) treated at our centre from Janu-
ary 2000 through to December 2011 were enrolled in the
study. Patients were prospectively identified from the hospi-
tal Infectious Diseases, Internal Medicine, Neurology, Cardi-
ology and Cardiac Surgery Departments, the Microbiology
Department’s blood culture registry, and the Echocardiogra-
phy Laboratory. All interventions were performed by the
same staff medical team during the entire study period,
including infectious disease specialists, microbiologists, cardi-
ologists and cardiac surgeons (endocarditis team). Every sin-
gle patient was evaluated early by a cardiac surgeon in order
to establish indication for surgery.
Patients who were referred for surgery from another cen-
tre at completion of antimicrobial treatment, those with
non-infective endocarditis, those with pacemaker infection
and no evidence of endocardial involvement and those with
isolated right-sided infective endocarditis were excluded
from the study. To preserve the assumption of independence
of observations, only the first episode of IE recorded for an
individual patient was included in the analysis.
Definitions
Infective endocarditis was defined as definite or possible
according to the modified Duke criteria [16]. Healthcare-
associated IE has been defined elsewhere [4]. Late prosthetic
endocarditis was defined as disease occurring more than
1 year after valve insertion. The Charlson index [17] was
used at admission to stratify overall co-morbidity. The indica-
tion for surgery was established according to current and
previous guidelines [18,19]. The EuroSCORE [20] was calcu-
lated for all patients with an indication for surgery. Unless
otherwise specified, surgery was performed during the active
phase of IE; that is, when the patient was still receiving
antibiotics.
Infective endocarditis complications were defined as the
development of any of the following conditions: (i) conges-
tive heart failure (CHF; new condition or worsening of a
known condition), (ii) paravalvular complication (diagnosed
by echocardiography or during surgery), (iii) new conduction
abnormality, (iv) stroke, (v) symptomatic systemic embo-
lism other than stroke, and (vi) acute renal failure (ARF),
established on a 25% increase in the baseline creatinine
concentration.
Follow-up was defined as the period between the day
after completing antimicrobial therapy to death or the last
control. Relapse was established on documentation of posi-
tive blood cultures caused by the same microorganism as the
initial endocarditis within the first 3 months after completing
antimicrobial treatment. Recurrence was defined as new
endocarditis caused by a different microorganism or infection
by the same microorganism as the initial endocarditis occur-
ring later than 3 months. Mortality was defined as death
from any cause while on antimicrobial treatment (in-hospital)
or during follow-up. The causes of in-hospital IE-related mor-
tality were listed as CHF, stroke, uncontrolled infection,
early postoperative death (when death occurred within
7 days after surgery), sudden death, and other causes. Non
IE-related in-hospital mortality was established as death due
to a cause not attributable to any IE complication in a stable
IE patient with no signs of active infection (defined as nega-
tive blood cultures after starting antimicrobial treatment, and
no evidence of septic metastasis or peniannular complica-
tions). Late surgery was defined as valve replacement for any
reason during follow-up.
Data collection
Demographic, clinical, diagnostic, treatment and follow-up
data were obtained by detailed chart abstraction with use of
standardized reporting forms and were entered into a data-
base created specifically for the purpose of this study (Micro-
soft Access 2000, 9.0.3821SR-I).
After completing antimicrobial therapy for IE, survivors
were prospectively followed-up. Two sets of blood speci-
mens for culture were taken 1 and 3 months later. Thereaf-
ter, patients were evaluated at regular intervals (usually
every 6–12 months) at the Cardiology Outpatient Depart-
ment, and at least one echocardiogram was performed
within the first year. Information on later valve surgery was
corroborated by means of the cardiac surgery registry. Due
to the strict geographical organizational structure in our
area, it is highly unlikely that patients who first attended our
hospital due to an endocarditis would undergo late surgery
in another centre. Late mortality data were obtained from
the patients’ clinical charts and were confirmed in all cases
at the end of the study by consulting the regional govern-
ment death registry.
Statistical analysis
Quantitative variables are reported as the median IQR and
qualitative variables as the number (%). The chi-square
test was used for comparing the distribution of categorical
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variables and the Student t-test for continuous variables. For
variables with a non-normal distribution, we used the Welch
test. Differences were considered to be statistically signifi-
cant at a p-value of <0.05. Univariate analysis was performed
to assess the influence of different variables on in-hospital
mortality. Variables that were determined to be clinically sig-
nificant and statistically significant in the univariate analysis
(p <0.1) were analysed by multivariate logistic regression
analysis using a stepwise backward procedure and choosing
the best model according to Mallows’ Cp statistics. The
goodness of fit of the final model was assessed by means of
the Nagelkerke test. For the cumulative 1-year mortality, we
only analysed episodes occurring before January 2011. The
life-table method was used to describe long-term mortality.
Differences between long-term mortality curves for NVIE
and PVIE patients were analysed with the log-rank test,
based on the Kaplan–Meier (product-limit) method. Statisti-
cal analyses were performed with Microsoft SPSS-PC+, ver-
sion 15.0 (SPSS, Chicago, IL, USA).
Results
During the study period, 505 episodes of infective endocardi-
tis in 485 patients were treated in our institution. After
application of the exclusion criteria, 438 episodes of LSIE
were analysed: 337 NVIE and 101 PVIE (66 late and 35
early). The general description of these cases is presented in
Table 1.
In-hospital mortality and cumulative 1-year mortality
One hundred and twenty-five of 438 patients (29%) died
during the active phase of infection, 86/337 (26%) with NVIE
and 39/101 (39%) with PVIE. One hundred of these 125
patients (80%) died due to causes directly related to endo-
carditis (Table 2). Of the remaining 25 patients, 12 died due
to nosocomial infection (six respiratory tract infections, two
urinary tract infections, two catheter-related bacteraemia,
one intra-abdominal infection and one of unknown origin),
eight due to massive bleeding (four digestive, two respiratory
and two other), three due to complications related to termi-
nal cancer (one disseminated aspergillosis, one massive pul-
monary thromboembolism and one respiratory insufficiency),
and two cirrhotic patients due to spontaneous bacterial
peritonitis.
The factors associated with in-hospital mortality in the
overall series are shown in Table 3. Percentages of in-hospi-
tal and 1-year mortality according to medical or combined
medical and surgical treatment for both NVIE and PVIE are
summarized in Table 4.
Relapses and recurrences
After completing antimicrobial therapy, the median follow-up
in survivors was 3.2 years (IQR, 1.0–6.0 years). The percent-
age of follow-up completeness was 97%. Nine patients were
lost to follow-up after a median follow-up of 0.3 years (IQR,
0.1–5.5 years). Relapses occurred in seven patients (2.2%;
95% CI, 1.1–4.5), three in NVIE (1.2%; 95% CI, 0.4–3.5) and
four in PVIE (6.5%; 95% CI, 2.5–15.4). The median time from
completion of antimicrobial treatment to relapse was 25 days
(IQR, 7–42 days), 12 days in NVIE (IQR, 4–16 days) and
35 days in PVIE (IQR, 26–56 days).
Recurrences were documented in eight patients (2.6%;
95% CI, 1.3–5.0), seven in NVIE (2.9%; 95% CI, 1.4–5.6) and
one in PVIE (1.6%; 95% CI, 0.3–8.6). The incidence density
was 0.0067 per patient-year (95% CI, 0.0029–0.0133), 0.0072
in NVIE (95% CI, 0.0029–0.0149) and 0.0046 in PVIE (95%
CI, 0.0001–0.0254). Tables 5 and 6 report relapses and
recurrences in detail.
Late surgery
Only four of 130 survivors (3.1%; 95% CI, 1.2–7.6) who
were treated surgically during the active phase of the disease
needed a second operation during follow-up, a median of
0.9 years (IQR, 0.1–1.8 years) after completing treatment:
one due to relapse, one due to recurrence, and two due to
progression of valve disease. None of them were re-oper-
ated on due to degeneration of a bioprosthesis previously
inserted during the active phase of endocarditis. However,
the percentage was 7.7% (95% CI, 4.6–12.4) (14/183) in sur-
vivors who had not undergone surgery during the first
admission (p 0.087), after a median of 1.3 years (IQR, 0.1–
2.9 years) following treatment. In this subgroup of patients,
late surgery was performed because of recurrence in two
patients and relapse in one; another patient underwent sur-
gery after completing antimicrobial treatment because of a
cerebral aneurysm. In the remaining ten patients, late surgery
was performed due to progression of valve disease.
Long-term mortality
Actuarial survival for the overall series was 60% at 1 year
(64% NVIE, 49% PVIE), 56% at 2 years (59% NVIE, 43% PVIE)
and 48% at 5 years (52% NVIE, 34% PVIE). In the 313
patients surviving to discharge, actuarial survival was 86% at
1 year (87% NVIE, 83% PVIE), 79% at 2 years (81% NVIE,
72% PVIE) and 68% at 5 years (71% NVIE, 57% PVIE). When
the mortality curves of NVIE and PVIE patients surviving the
first episode were compared, clinically significant differences
were found (p 0.056) (Fig. 1).
At 1 year, 115 of 397 patients (29.0%; 95% CI, 24.7–33.6)
remained alive with no surgery requirement, relapse or
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recurrence (NVIE 85/309 (27.5%; 95% CI, 22.8–32.7), PVIE
30/88 (34.1%; 95% CI, 25.0–44.5)). At the end of follow-up,
209 patients were alive and 91 (44%) of them did not
require valve surgery at any time during admission or follow-
up, 64/173 (37%) with NVIE and 27/36 (75%) with PVIE.
Discussion
The overall in-hospital mortality of LSIE in this contemporary
cohort was 29%, mainly due to CHF (30%) and non-IE-
TABLE 1. Main epidemiological,
clinical and evolutive findings of
438 episodes of left-sided infective
endocarditis
Clinical characteristic
Native valve IE
(n = 337)
Prosthetic valve
IE (n = 101)
Overall
(n = 438)
Age, years 65.2 (49.7–74.6) 68.7 (61.3–76.3) 66.4 (51.8–74.9)
Male sex 221 (66) 64 (63) 285 (65)
Modified Duke criteria, definite 299 (89) 87 (86) 386 (88)
Transferred from other centres 136 (40) 34 (34) 170 (39)
HAIE 94 (28) 41 (41) 135 (31)
Aortic valve affected 198 (59) 60 (59) 258 (59)
Co-morbidities
Charlson index 1 (0–3) 2 (1–3) 2 (0–3)
Diabetes mellitus 70 (21) 29 (29) 99 (23)
Cancer 48 (14) 8 (8) 56 (13)
Immunosuppressive treatment 22 (7) 2 (2) 24 (6)
Haemodialysis 19 (6) 3 (3) 22 (5)
HIV infection 14 (4) 1 (1) 15 (3)
Intravenous drug use 11 (3) 1 (1) 12 (3)
Aetiology
Streptococci 138 (41) 25 (25) 163 (37)
viridans-group streptococci 85 (25) 18 (18) 103 (24)
Streptococcus bovis 28 (8) 5 (5) 33 (8)
Other streptococci 25 (7) 2 (2) 27 (6)
Staphylococci 109 (32) 34 (34) 143 (33)
Staphylococcus aureus 85 (25) 14 (14) 99 (23)
Methicillin-resistant S. aureus 17/85 (20) 6/14 (43) 23/99 (23)
Coagulase-negative staphylococci 24 (7) 20 (20) 44 (10)
Enterococci 42 (13) 17 (17) 59 (14)
Gram-negative rods (GNR) 11 (3) 8 (8) 19 (4)
Non-HACEK GNR 6 (2) 4 (4) 10 (2)
HACEK group 5 (2) 4 (4) 9 (2)
Other microorganisms 20 (6) 10 (10) 30 (7)
Unknown aetiology 17 (5) 7 (7) 24 (6)
Presence of any complication 284 (84) 81 (80) 365 (83)
Congestive heart failure 166 (49) 39 (39) 205 (47)
Acute renal failure 112 (33) 40 (40) 152 (35)
Embolism other than stroke 114 (34) 19 (19) 133 (30)
Paravalvular complication 77 (23) 40 (40) 117 (27)
Stroke 69 (21) 20 (20) 89 (20)
New conduction abnormality 65 (19) 19 (19) 84 (19)
Surgery during the active phase of infection
Indication for surgery 244 (72) 74 (73) 318 (73)
Hemodynamic 207/244 (85) 43/74 (58) 250/318 (79)
Uncontrolled infection 89/244 (37) 58/74 (78) 147/318 (46)
Embolic 120/244 (49) 27/74 (37) 147/318 (46)
Surgery performed 144 (43) 30 (30) 174 (40)
EuroSCORE when surgery performed 8 (6–11) 12.5 (11–15) 9 (9–12)
EuroSCORE when surgery indicated
but not performed
10 (8–12) 13 (9–16) 11 (8–13)
Reasons for no surgery when indicated
Good evolution without surgery 33/100 (33) 12/44 (27) 45/144 (31)
Critical status 23/100 (23) 14/44 (32) 37/144 (26)
Unaffordable surgical risk 17/100 (17) 10/44 (23) 27/144 (19)
Co-morbid basal status 18/100 (18) 5/44 (11) 23/144 (16)
Surgery scheduled after discharge 5/100 (5) 1/44 (2) 6/144 (4)
Surgeon declined to operate 2/100 (2) 2/44 (5) 4/144 (3)
Patient refused operation 2/100 (2) – 2/144 (1)
Type of surgery
Mechanical prosthesis 111 (77) 24 (80) 135 (78)
Bioprosthesis 30 (21) 6 (20) 36 (21)
Repair 3 (2) – 3 (2)
Outcome
In-hospital mortality 86 (26) 39 (39) 125 (29)
Cumulative 1-year mortalitya 107/309 (35) 43/88 (49) 150/397 (38)
Relapseb 3/251 (1) 4/62 (6) 7/313 (2)
Recurrenceb 7/251 (3) 1/62 (2) 8/313 (3)
Values are reported as n (%) or median (interquartile range).
IE, infective endocarditis; HAIE, healthcare-associated infective endocarditis; HIV, human immunodeficiency virus;
HACEK, Haemophilus species, Aggregatibacter actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens and
Kingella species.
aIncludes 397 episodes from January 2000 until December 2010.
bIncludes 313 patients alive at the end of antimicrobial therapy.
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related causes (20%). The risk of mortality was lowest in
patients who did not have an indication for surgery during
the active phase of infection (13% in-hospital, 27% 1 year),
and was greatest in patients in whom surgery was indicated
but not performed (46% in-hospital, 58% 1 year). Relapse
and recurrence were both uncommon complications in survi-
vors (2.2% and 2.6%, respectively). For those alive at the end
of antimicrobial therapy, survival was 79% and 68%, at 2 and
5 years, respectively, and the overall need for valve replace-
ment during follow-up was 6%.
When comparing our current results with those previ-
ously reported by our group [10], we found epidemiological
differences in the group of patients with NVIE. First, there
was a three-fold increase in the number of NVIE cases, while
during the same time period there was an 30% increase in
TABLE 2. Causes of in-hospital mortality in 125 episodes of
left-sided infective endocarditis
Cause of death
Native
valve IE
(n = 86)
Prosthetic
valve IE
(n = 39)
Overall
(n = 125)
Congestive heart failure 26 (30) 12 (31) 38 (30)
Stroke 16 (19) 5 (13) 21 (17)
Ischaemic, n 8 0 8
Intracranial haemorrhage, n 8 5 13
Uncontrolled infection 9 (11) 8 (21) 17 (14)
Immediate post-surgical complication 8 (9) 5 (13) 13 (10)
Sudden death 5 (6) 3 (8) 8 (6)
Other IE complications 2a (2) 1b (3) 3 (2)
Death unrelated to IE 20 (23) 5 (13) 25 (20)
Values are reported as n (%), unless otherwise noted.
IE, infective endocarditis.
aMultiorgan failure due to embolic lower limb ischaemia in one, and aortic rup-
ture 28 days after surgery in one.
bMultiorgan failure secondary to wound infection after lower limb amputation
due to embolic ischaemia.
TABLE 3. Univariate and multivariate analysis of in-hospital mortality in all 438 episodes of lef-sided infective endocarditis
Characteristic Alive (n = 313) Dead (n = 125)
Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
Age, years 63.9 (49.4–74.0) 70.1 (60.6–76.3) 1.03 (1.01–1.04) 0.001
Male sex 210 (67) 75 (60) 0.7 (0.5–1.1) 0.160
HAIE 76 (24) 59 (47) 2.8 (1.8–4.3) <0.001 2.0 (1.1–3.6) 0.018
Prosthetic valve 62 (20) 39 (31) 1.8 (1.2–2.9) 0.011 1.9 (1.1–3.5) 0.033
Aortic valve 197 (63) 61 (49) 0.6 (0.4–0.9) 0.007
Charlson index 1 (0–3) 2 (1–4) 1.3 (1.2–1.4) <0.001 1.3 (1.1–1.4) 0.001
Immunosuppression 11 (4) 13 (10) 3.1 (1.4–7.3) 0.006
Diabetes mellitus 60 (19) 39 (31) 1.9 (1.2–3.1) 0.007
Cancer 38 (12) 18 (14) 1.2 (0.7–2.2) 0.52
Staphylococci 77 (25) 66 (53) 3.4 (2.2–5.3) <0.001
Staphylococcus aureus 53 (17) 46 (37) 2.9 (1.8–4.6) <0.001 2.0 (1.2–3.5) 0.011
MRSA 8/53 (15) 15/46 (33) 2.7 (1.0–7.2) 0.044
Enterococci 41 (13) 18 (14) 1.1 (0.6–2.0) 0.72
Streptococci 138 (44) 25 (20) 0.3 (0.2–0.5) <0.001
Any complication 241 (77) 124 (99) 37.0 (5.1–270.8) <0.001
ARF 79 (25) 73 (58) 4.2 (2.7–6.4) <0.001 3.3 (1.9–5.6) <0.001
Stroke 44 (14) 45 (36) 3.4 (2.2–5.3) <0.001 3.8 (2.1–6.9) <0.001
CHF 120 (38) 85 (68) 3.4 (2.1–5.6) <0.001 3.8 (2.1–7.0) <0.001
Surgery indicated 209 (67) 109 (87) 3.4 (1.9–6.0) <0.001 3.2 (1.5–6.9) 0.003
Surgery not donea 79 (25) 65 (52) 2.4 (1.5–3.9) <0.001
Surgery performed 130 (42) 44 (35) 0.8 (0.5–1.2) 0.22 0.4 (0.2–0.7) 0.003
Values are reported as n (%) or median (interquartile range).
HAIE, healthcare-associated infective endocarditis; MRSA, methicillin-resistant Staphylococcus aureus; CHF, congestive heart failure; ARF, acute renal failure.
aWhen surgery indicated.
TABLE 4. In-hospital and 1-year mortality according to medical or combined medical and surgical treatment during the active
phase of infection
In-hospital mortality Cumulative 1-year mortalitya
Overall Native IE Prosthetic IE Overall Native IE Prosthetic IE
Surgery not indicated 16/120 (13) 15/93 (16) 1/27 (4) 29/108 (27) 27/85 (32)b 2/23 (9)
Surgery indicated and performed 44/174 (25) 28/144 (19) 16/30 (53) 44/155 (28) 27/129 (21) 17/26 (65)
Surgery indicated, not performed 65/144 (46) 43/100 (43) 22/44 (50)c 77/134 (58) 53/95 (56) 24/39 (62)d
Values are reported as n/N (%).
IE, infective endocarditis.
aIncludes only 397 cases up to December 2010.
bThirteen of 14 patients alive at the end of antimicrobial therapy died during the first year of follow-up due to baseline co-morbidities. The remaining patient died due to an
unknown cause.
cTwelve of 22 patients alive at the end of antimicrobial therapy had a theoretical indication for cardiac surgery (seven isolated small (<5 mm) paravalvular abscess, three
severe valve regurgitation without heart failure, and two infections caused by staphylococci), but it was not performed because of good evolution without being operated on.
dEight out of 15 patients alive at 1 year had a theoretical indication for cardiac surgery (seven isolated small (<5 mm) paravalvular abscess, and one severe valve regurgitation
without heart failure), but it was not performed because of good evolution without being operated on.
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the general population in our geographical area. Moreover,
surgery and in-hospital mortality were more frequent in the
contemporary group than in the early one (43% vs. 34%, p
0.087; and 26% vs. 16%, p 0.020, respectively). The median
age of survivors was higher in the contemporary group (63
vs. 47 years), and there was an increase in the percentage of
enterococcal (13% vs. 5%, p 0.007) and staphylococcal infec-
tions (25% vs. 8% overall, p <0.0001; 20% vs. 4% for S. aur-
eus, p <0.0001), as well as higher rates of diabetes and
cancer. Although relapses were similar in both groups (2.2%
vs. 2.7%, p 0.378), the recurrence rate doubled in the con-
temporary cohort (0.0072 vs. 0.0030 episodes per person-
year) and mortality was higher in recurring patients (75% vs.
20%, p 0.103). Lastly, late surgery was lower in the contem-
porary study than in the previous one (6% vs. 36% overall,
p <0.0001), and survival was worse: 81% vs. 90% at 2 years
(p 0.027) and 71% vs. 88% at 5 years (p <0.0001). Along the
same lines, a recent French paper described important
changes in IE epidemiology throughout the last two decades
[21].
The overall in-hospital mortality in our study was high
(29%), but it is the same as the value reported in another
contemporary Spanish series [1]. It should be stressed that
in both series the sample included all consecutive patients
admitted to any hospital ward and diagnosed with infective
endocarditis. In our opinion, the risk of in-hospital mortality
we found was influenced by at least two factors. First, IE has
undergone many epidemiological changes, as has been widely
described [2,22,23], and our results corroborate this. Nowa-
days, about 30% of all IE episodes are associated with the
healthcare system [2,4] in fragile patients, in whom the risk
of death is inherently high, regardless of the type of IE, and
in whom surgical decisions are particularly difficult. Second,
39% of our IE patients are transferred from community hos-
pitals, which can negatively determine the prognosis of some
patients (due to either IE-related complications or subopti-
mal management at origin) [24], who would benefit from
specialized multidisciplinary teams [25]. In our multivariate
analysis of risk factors for in-hospital mortality, the model
highlighted the importance of healthcare acquisition, pros-
thetic valves, infection, basal co-morbid status, S. aureus
infection, acute renal failure, stroke and congestive heart fail-
ure as risk factors for death, and the benefit of prompt sur-
gery, in keeping with previous reports [1,2,4,26].
TABLE 5. Description of seven episodes of relapse
Age,
years Sex
Underlying
condition Aetiology Valve affected
Surgery during
active phase of IE
Days until
relapsea
Treatment
of relapse
Final status
(follow-up, years)b
70.9 Female Child C cirrhosis S. epidermidis Mitral prosthetic Not performedc 42 Medicald Alive (0.4)e
61.6 Male CRF S. mitis Mitral prosthetic Not indicated 27 Medical Cured (0.5)
70.1 Male CRF, stroke E. faecalis Aortic prosthetic Not indicated 61 Medical Cured (3.8)
88.5 Male CRF, CPD E. faecalis Aortic prosthetic Not performedc 25 Medical Cured (1.1)
77.8 Male Diabetes S. gallolyticus Aortic native Not performedf 16 Surgical Cured (3.3)
48.1 Male CPD S. gordonii Mitral native Performedg 4 Medical Cured (2.2)
71.3 Female None c-MRSA Mitral valve Performedh 7 Surgical Cured (0.3)
IE, infective endocarditis; CRF, chronic renal failure; CPD, chronic pulmonary disease; c-MRSA, community-acquired methicillin-resistant Staphylococcus aureus.
aDays from completion of antimicrobial therapy to relapse.
bYears from last day of treatment to last day of follow-up.
cSurgery indicated but not performed because of high surgical risk.
dOral suppressive antimicrobial treatment.
eIn this case, years from start of suppressive treatment.
fSurgery scheduled soon after discharge.
gIncomplete resection of vegetations.
hSurgery performed 24 h after start of antimicrobial therapy.
TABLE 6. Description of eight episodes of recurrence
Age,
years Sex Aetiology
Valve
affected
Surgery during
first episode
Years to
recurrencea
Second
aetiology
Valve affected
second episode
Surgery during
second episode
Final status
(follow-up, years)b
66.2 Male S. sanguis Aortic native Not performedc 3.7 S. mitis Mitral native Performed Death (–)
31.0 Male S. mitis Mitral native Not performedd 1.2 Streptococcus spp. Mitral native Not indicated Death (–)
91.0 Male E. coli Mitral native Not indicated 0.2 Candida albicans Mitral native Not performedc Death (–)
72.1 Male S. viridans Mitral native Not performedc 0.7 S. epidermidis Mitral native Not performedc Alive (2.2)
45.1 Female S. mitis Mitral native Not indicated 0.6 S. mitis Aortic native Not performede Death (–)
77.8 Female S. aureus Mitral native Performed 0.3 Candida albicans Mitral prosthetic Not performedc Death (–)
68.0 Male S. aureus Mitral native Performed 0.9 E. faecalis Mitral prosthetic Performed Alive (5.3)
77.4 Male S. anginosus Aortic native Performed 1.7 S. agalactiae Aortic prosthetic Performed Death (–)
aYears from last day of treatment of first episode to recurrence.
bYears from end of antimicrobial treatment for the last episode.
cSurgery indicated but not performed because of high surgical risk.
dGood evolution without surgery.
eEnd-stage multiple sclerosis.
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To the best of our knowledge, our series provides the
most detailed description of in-hospital mortality in LSIE
patients. Of note, 20% of patients died due to non-IE-related
causes, which is consistent with a high rate of healthcare-
associated infections in patients with considerable co-mor-
bidities [9].
Although there are few randomized clinical trials regarding
the influence of valve surgery on the prognosis of infective
endocarditis (one of them is still recruiting patients [27] and
another one is focused on young people with streptococcal
IE [28]), there is growing evidence that early valve surgery is
beneficial [26], especially in patients with CHF [29]. More-
over, two studies have shown that not performing surgery in
patients in whom it is indicated is a risk factor for death
[30,31]. In the present study, 33% of IE patients had an indi-
cation for surgery, but it was not undertaken, in most cases
because of an extremely high surgical risk that contraindi-
cated the operation. This fact perfectly explains the highest
mortality in the subgroup of patients who had an indication
for surgery, but in whom surgery was not performed, and
the lowest in the subgroup of less severely ill patients in
whom surgery was not required. However, in-hospital mor-
tality for PVIE patients with an indication for surgery did not
differ between patients undergoing surgery or not. This fact
could be explained because 12 of 22 patients in this last sub-
group were not surgically treated due to a good clinical evo-
lution, thus illustrating the difficulties in establishing the
criteria for surgery. On the other hand, 1-year mortality did
not differ in NVIE patients not requiring surgery and those
undergoing it, because of an excess of non-related IE mortal-
ity during follow-up in the former. Anyway, the analysis of
the influence of surgery on mortality is always difficult, and
subject to the different methodological approaches [32].
Relapses and recurrences remain as uncommon late com-
plications of LSIE. Even though we may be faced with more
difficult microorganisms and patients who cannot undergo
surgery because of high surgical risk, the relapse rate has not
changed in our institution, and when relapse occurs it can be
successfully treated with or without surgery. Recurrences
are of greater concern, because the current rate in NVIE is
double that of our previous study, and recurrence is associ-
ated with high in-hospital mortality.
The need for late surgery decreased significantly from our
first study [10], in which it was found that aortic valve
involvement was a risk factor for requiring surgery after
finalizing medical treatment. Since then, all patients with
severe aortic valve regurgitation are considered for surgery
during the active phase of infection regardless of whether
they have CHF or not.
The incidence of late mortality was high, but as has been
reported, long-term mortality does not depend on the medi-
cal or surgical treatment received during admission [15,33],
but instead on baseline conditions, such as age and co-mor-
bidities [14,34].
This study has some limitations. First, it was conducted in
a referral centre, and our results may not reflect the epide-
miology of community hospitals or other geographical areas.
However, the single-centre design can also be considered a
strength because our series was homogeneous in the treat-
ment decisions, which were taken by a multidisciplinary team
aware of the most recent developments in endocarditis and
its guidelines; comparison with our earlier study illustrates
the substantial epidemiological changes that have occurred in
the last decades. Second, our experience is subject to refer-
ral bias due to the team’s emerging profile as a centre of
excellence for IE over the period of study. Third, it is possi-
ble that some cases of recurrent disease were not recorded,
especially in patients who did not require cardiac surgery
and were living far from the hospital. This is not the case in
relapses, as blood cultures following treatment are systemati-
cally performed in our hospital. Also, there were no con-
cerns regarding the recording of late deaths because we
verified every case in the government death registry. Impor-
tantly, the percentage of cases lost to follow-up was very
low in this series, an indication of the strength of the study.
In conclusion, this study, together with our previous
report, shows the prognostic changes of LSIE occurring over
the last 30 years. Nowadays, in-hospital and long-term
FIG. 1. Survival curve of patients alive at completion of antimicrobial
therapy, according to native or prosthetic valve left-sided infective
endocarditis (p 0.056). LSIE, left-sided infective endocarditis.
E528 Clinical Microbiology and Infection, Volume 18 Number 12, December 2012 CMI
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E522–E530
mortality rates are high, especially in PVIE, because of our
patients’ clinical characteristics. Even though a large number
of patients could not undergo surgery, relapses were uncom-
mon with the present approach for managing this disease,
and the need for late surgery was greatly reduced. Although
recurrences were infrequent, they were associated with high
mortality. This fact, as well as the better prognosis of
patients not needing surgery, is an indication that consider-
able emphasis should be placed on the prevention and
prompt diagnosis of new IE episodes.
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